News

Interview with Joel S. Freundlich



Dr. Joel S. Freundlich
Dr. Joel S. Freundlich



Dr. Joel S. Freundlich attended Cornell University as a McMullen scholar and an Exxon scholar, attaining his B.S. degree with Distinction in Chemical Engineering in 1991 and his M. Eng. degree in Chemical Engineering in 1992. He received his Ph.D. degree in 1996 in Organic Chemistry with Richard R. Schrock – the 2005 Nobel Prize in Chemistry recipient. Dr. Freundlich was an active researcher in the biotech industry for ten years. His achievements are highlighted by contributions to three clinical submissions.

He is currently a Senior Research Scientist in the Biochemistry and Biophysics department at Texas A&M University and a Visiting Professor at Rutgers University in the Medicinal Chemistry department. His research seeks to leverage chemical techniques to 1) understand critical biological processes within Mtb that are essential to its lifecycle and interactions with the human immune system and 2) leverage this knowledge of essential enzyme and/or pathways to seed the discovery of novel antitubercular drugs.

This interview was conducted at JHU on November 13, 2009.

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...